<DOC>
	<DOCNO>NCT01065038</DOCNO>
	<brief_summary>Study AOP 03-007 design pivotal study test , Anagrelide ( Thromboreductin® ) inferior HU respect efficacy patient ET . This approach demonstrate non-inferiority base follow decision point : • ET rare disease recruitment large patient number ( &gt; 1600 ) prove superiority consider possible . . It decide recruit treatment naïve high risk patient avoid pre-treatment bias , limited number patient eligible study .</brief_summary>
	<brief_title>Anagrelide vs. Hydroxyurea - Efficacy Tolerability Study Patients With Essential Thrombocythaemia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Presence essential thrombocythaemia highrisk profile . previous treatment cytoreductive drug Anagrelide pregnant woman woman childbearing age inadequate contraception patient contraindication study drug due anaphylactoid reaction either active nonactive ingredient know lactose intolerance cardiovascular disease grade IIIIV ( Toxicity Criteria South West Oncology Group , 1992 ) negative benefit/risk ratio severe renal disease ( Creatinin Clearance &lt; 30 ml/min ) severe liver disease ( AST ALT &gt; 5times normal ) coexisting , malignant , systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>